NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
13.81
-0.22 (-1.57%)
Mar 9, 2026, 2:57 PM EDT - Market open
NeuroPace Revenue
In the year 2025, NeuroPace had annual revenue of $99.99M with 25.13% growth. NeuroPace had revenue of $26.59M in the quarter ending December 31, 2025, with 23.86% growth.
Revenue (ttm)
$99.99M
Revenue Growth
+25.13%
P/S Ratio
4.64
Revenue / Employee
$478,402
Employees
209
Market Cap
464.94M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Orthofix Medical | 822.31M |
| Bioventus | 568.09M |
| OrthoPediatrics | 236.35M |
| Cerus | 206.13M |
| Cytek Biosciences | 201.49M |
| Pacific Biosciences of California | 160.01M |
| Beta Bionics | 100.25M |
NPCE News
- 3 days ago - NeuroPace to Present at the Leerink Global Healthcare Conference - Business Wire
- 5 days ago - NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook - Business Wire
- 16 days ago - NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Business Wire
- 7 weeks ago - NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
- 2 months ago - NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Business Wire